This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Elevated HMGB1 mediates microbiome-immune axis dysregulation underlying reduced neutralization capacity in obesity-related post-acute sequelae of SARS-CoV-2 (preprint)
researchsquare; 2023.
Препринт
в английский
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2973496.v1
ABSTRACT
While obesity is a risk factor for post-acute sequelae of SARS-CoV-2 infection (PASC, "long-COVID"), the mechanism(s) underlying this phenomenon is poorly understood. To address this gap in knowledge, we performed a 6-week longitudinal study to examine immune activity and gut microbiome dysbiosis in post-acute stage patients recovering from SARS-CoV-2 infection. Self-reported symptom frequencies and blood samples were collected weekly, with plasma assessed by ELISA and Luminex for multiple biomarkers and immune cell profiling. DNA from stool samples were collected at the early stage of recovery for baseline assessments of gut microbial composition and diversity using 16S-based sequencing. Multiple regression analyses revealed obesity-related PASC linked to a proinflammatory immune profile and reduced adaptive immunity, corresponding with gut microbial dysbiosis. In particular, the high mobility group box 1 (HMGB1) protein was found to be a central mediator of this dysregulation, with its upregulated levels in plasma associated with significantly impaired viral neutralization that was exacerbated with obesity. Plasma levels of HMGB1 also negatively correlated with B-cell activating factor (BAFF), while inducing pro-inflammatory nitric oxide. These findings strongly implicate HMGB1 as a candidate biomarker of PASC, with potential applications for risk assessment and targeted therapies.
Полный текст:
Имеется в наличии
Коллекция:
Препринты
база данных:
PREPRINT-RESEARCHSQUARE
Основная тема:
Dysbiosis
/
COVID-19
/
Obesity
Язык:
английский
Год:
2023
Тип:
Препринт
Документы, близкие по теме
MEDLINE
...
LILACS
LIS